Trial Profile
Randomized, Double-Blind Phase III study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Nov 2013
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 24 May 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center: CTSU-E2810).
- 05 Mar 2013 New trial record